The Biopharma Excellence team has deep experience with cell and gene therapies and is working hand in hand with us to help realize our ambitious vision.
Where do you need our help?
The Science Huddle: 20 years of Biosimilars: Are We on the Right Track?
For nearly 20 years, biosimilars have been at the center of a great debate with 2022 seen as a pivotal point as more of these biologic similars came to market. The debate has progressed from viability and feasibility to sustainability with cost, regulatory guidelines, incentives, efficacy, and patent expirations at the center of today’s industry discussion. As more biosimilars prove they can deliver new competition and lower costs to patient-critical treatments, the dialogue is shifting.
Bridging the Biotech / Regulator Divide
We help dynamic biopharma companies bring innovative new therapies to market in the smartest, smoothest and safest way possible.
We work closely with biopharma businesses, international regulators and health authorities, and potential investors, to confidently optimize the market potential of cutting-edge biotech innovation.
Our team is a fusion of three scientific powerhouses, Pharmalex, ERA Consulting and Biopharma Excellence – under the PharmaLex brand. We combine 35+ years of empirical experience and respected regulator relationships.